# Arcus Biosciences, Inc.: financial statements, quarterly

RCUS · NYSE · CIK 1724521 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rcus.md) · [Financials](/companies/rcus/financials.md) · [Filings](/companies/rcus/filings.md) · [Insiders](/companies/rcus/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rcus/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [32.0](/filings/0001724521-24-000160.md) | [(49.0) d](/filings/0001724521-26-000009.md) | [10.0](/filings/0001724521-25-000063.md) | [11.0](/filings/0001724521-25-000101.md) | [7.0](/filings/0001724521-25-000116.md) | [23.0 d](/filings/0001724521-26-000009.md) | [8.0](/filings/0001724521-26-000034.md) | [8.0](/filings/0001724521-26-000044.md) | [6.0](/filings/0001724521-25-000116.md) | [11.0 d](/filings/0001724521-26-000009.md) | [7.0](/filings/0001724521-26-000034.md) | [33.0](/filings/0001724521-26-000044.md) |
| Research and development | $m | [82.0](/filings/0001724521-24-000160.md) | [93.0 d](/filings/0001724521-26-000009.md) | [109](/filings/0001724521-25-000063.md) | [115](/filings/0001724521-25-000101.md) | [123](/filings/0001724521-25-000116.md) | [101 d](/filings/0001724521-26-000009.md) | [122](/filings/0001724521-26-000034.md) | [139](/filings/0001724521-26-000044.md) | [141](/filings/0001724521-25-000116.md) | [121 d](/filings/0001724521-26-000009.md) | [122](/filings/0001724521-26-000034.md) | [113](/filings/0001724521-26-000044.md) |
| Operating income | $m | [(80.0)](/filings/0001724521-24-000160.md) | [(91.0) d](/filings/0001724521-26-000009.md) | [(16.0)](/filings/0001724521-25-000063.md) | [(106)](/filings/0001724521-25-000101.md) | [(105)](/filings/0001724521-25-000116.md) | [(103) d](/filings/0001724521-26-000009.md) | [(122)](/filings/0001724521-26-000034.md) | [(8.0)](/filings/0001724521-26-000044.md) | [(142)](/filings/0001724521-25-000116.md) | [(114) d](/filings/0001724521-26-000009.md) | [(134)](/filings/0001724521-26-000034.md) | [(96.0)](/filings/0001724521-26-000044.md) |
| Interest expense | $m | [1.0](/filings/0001724521-24-000160.md) | [0.0 d](/filings/0001724521-26-000009.md) | [1.0](/filings/0001724521-25-000063.md) | [0.0](/filings/0001724521-25-000101.md) | [1.0](/filings/0001724521-25-000116.md) | [2.0 d](/filings/0001724521-26-000009.md) | [1.0](/filings/0001724521-26-000034.md) | [2.0](/filings/0001724521-26-000044.md) | [3.0](/filings/0001724521-25-000116.md) | [2.0 d](/filings/0001724521-26-000009.md) | [3.0](/filings/0001724521-26-000034.md) | [3.0](/filings/0001724521-26-000044.md) |
| Income tax | $m | [2.0](/filings/0001724521-24-000160.md) | [1.0 d](/filings/0001724521-26-000009.md) | [0.0](/filings/0001724521-25-000063.md) | [0.0](/filings/0001724521-25-000101.md) | [0.0](/filings/0001724521-25-000116.md) | [1.0 d](/filings/0001724521-26-000009.md) | [0.0](/filings/0001724521-26-000034.md) | [0.0](/filings/0001724521-26-000044.md) | [0.0](/filings/0001724521-25-000116.md) | [0.0 d](/filings/0001724521-26-000009.md) | [0.0](/filings/0001724521-26-000034.md) | [0.0](/filings/0001724521-26-000044.md) |
| Net income | $m | [(71.0)](/filings/0001724521-24-000160.md) | [(81.0) d](/filings/0001724521-26-000009.md) | [(4.0)](/filings/0001724521-25-000116.md) | [(93.0)](/filings/0001724521-25-000116.md) | [(92.0)](/filings/0001724521-25-000116.md) | [(94.0) d](/filings/0001724521-26-000009.md) | [(112)](/filings/0001724521-26-000044.md) | [0.0](/filings/0001724521-26-000044.md) | [(135)](/filings/0001724521-25-000116.md) | [(106) d](/filings/0001724521-26-000009.md) | [(128)](/filings/0001724521-26-000044.md) | [(91.0)](/filings/0001724521-26-000044.md) |
| Diluted EPS | $ per share | [(0.94)](/filings/0001724521-24-000160.md) | not reported | [(0.05)](/filings/0001724521-25-000063.md) | [(1.02)](/filings/0001724521-25-000101.md) | [(1.00)](/filings/0001724521-25-000116.md) | not reported | [(1.14)](/filings/0001724521-26-000034.md) | [0.00](/filings/0001724521-26-000044.md) | [(1.27)](/filings/0001724521-25-000116.md) | not reported | [(1.02)](/filings/0001724521-26-000034.md) | [(0.72)](/filings/0001724521-26-000044.md) |
| Basic EPS | $ per share | [(0.94)](/filings/0001724521-24-000160.md) | not reported | [(0.05)](/filings/0001724521-25-000063.md) | [(1.02)](/filings/0001724521-25-000101.md) | [(1.00)](/filings/0001724521-25-000116.md) | not reported | [(1.14)](/filings/0001724521-26-000034.md) | [0.00](/filings/0001724521-26-000044.md) | [(1.27)](/filings/0001724521-25-000116.md) | not reported | [(1.02)](/filings/0001724521-26-000034.md) | [(0.72)](/filings/0001724521-26-000044.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [184](/filings/0001724521-24-000160.md) | [127](/filings/0001724521-25-000040.md) | [185](/filings/0001724521-25-000063.md) | [156](/filings/0001724521-25-000101.md) | [201](/filings/0001724521-25-000116.md) | [150](/filings/0001724521-26-000009.md) | [192](/filings/0001724521-26-000034.md) | [248](/filings/0001724521-26-000044.md) | [238](/filings/0001724521-25-000116.md) | [222](/filings/0001724521-26-000044.md) | [201](/filings/0001724521-26-000034.md) | [150](/filings/0001724521-26-000044.md) |
| Current assets | $m | [882](/filings/0001724521-23-000021.md) | [831](/filings/0001724521-25-000040.md) | [1,064](/filings/0001724521-24-000092.md) | [1,022](/filings/0001724521-24-000138.md) | [1,127](/filings/0001724521-24-000160.md) | [1,016](/filings/0001724521-26-000009.md) | [1,031](/filings/0001724521-25-000063.md) | [946](/filings/0001724521-25-000101.md) | [857](/filings/0001724521-25-000116.md) | [1,007](/filings/0001724521-26-000044.md) | [844](/filings/0001724521-26-000034.md) | [756](/filings/0001724521-26-000044.md) |
| Total assets | $m | [1,191](/filings/0001724521-23-000021.md) | [1,095](/filings/0001724521-25-000040.md) | [1,293](/filings/0001724521-24-000092.md) | [1,186](/filings/0001724521-24-000138.md) | [1,252](/filings/0001724521-24-000160.md) | [1,150](/filings/0001724521-26-000009.md) | [1,156](/filings/0001724521-25-000063.md) | [1,075](/filings/0001724521-25-000101.md) | [974](/filings/0001724521-25-000116.md) | [1,139](/filings/0001724521-26-000044.md) | [997](/filings/0001724521-26-000034.md) | [924](/filings/0001724521-26-000044.md) |
| Current liabilities | $m | [200](/filings/0001724521-23-000021.md) | [184](/filings/0001724521-25-000040.md) | [204](/filings/0001724521-24-000092.md) | [199](/filings/0001724521-24-000138.md) | [215](/filings/0001724521-24-000160.md) | [226](/filings/0001724521-26-000009.md) | [192](/filings/0001724521-25-000063.md) | [210](/filings/0001724521-25-000101.md) | [235](/filings/0001724521-25-000116.md) | [231](/filings/0001724521-26-000044.md) | [209](/filings/0001724521-26-000034.md) | [198](/filings/0001724521-26-000044.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Long-term debt | $m | not reported | [0.0](/filings/0001724521-25-000040.md) | not reported | not reported | [47.0](/filings/0001724521-24-000160.md) | [48.0](/filings/0001724521-26-000009.md) | [48.0](/filings/0001724521-25-000063.md) | [97.0](/filings/0001724521-25-000101.md) | [98.0](/filings/0001724521-25-000116.md) | [99.0](/filings/0001724521-26-000044.md) | [100](/filings/0001724521-26-000034.md) | [101](/filings/0001724521-26-000044.md) |
| Shareholders' equity | $m | [520](/filings/0001724521-24-000160.md) | [462](/filings/0001724521-26-000009.md) | [707](/filings/0001724521-25-000116.md) | [635](/filings/0001724521-25-000116.md) | [565](/filings/0001724521-25-000116.md) | [485](/filings/0001724521-26-000044.md) | [531](/filings/0001724521-26-000044.md) | [549](/filings/0001724521-26-000044.md) | [436](/filings/0001724521-25-000116.md) | [631](/filings/0001724521-26-000044.md) | [524](/filings/0001724521-26-000044.md) | [464](/filings/0001724521-26-000044.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(63.0) d](/filings/0001724521-24-000160.md) | [(88.0) d](/filings/0001724521-26-000009.md) | [(2.0)](/filings/0001724521-25-000063.md) | [(94.0) d](/filings/0001724521-25-000101.md) | [26.0 d](/filings/0001724521-25-000116.md) | [(100) d](/filings/0001724521-26-000009.md) | [(132)](/filings/0001724521-26-000034.md) | [(133) d](/filings/0001724521-26-000044.md) | [(97.0) d](/filings/0001724521-25-000116.md) | [(120) d](/filings/0001724521-26-000009.md) | [(138)](/filings/0001724521-26-000034.md) | [(119) d](/filings/0001724521-26-000044.md) |
| Capital expenditure | $m | [10.0 d](/filings/0001724521-24-000160.md) | [6.0 d](/filings/0001724521-26-000009.md) | [4.0](/filings/0001724521-25-000063.md) | [0.0 d](/filings/0001724521-25-000101.md) | [1.0 d](/filings/0001724521-25-000116.md) | [1.0 d](/filings/0001724521-26-000009.md) | [1.0](/filings/0001724521-26-000034.md) | [0.0 d](/filings/0001724521-26-000044.md) | [0.0 d](/filings/0001724521-25-000116.md) | [1.0 d](/filings/0001724521-26-000009.md) | [0.0](/filings/0001724521-26-000034.md) | [0.0 d](/filings/0001724521-26-000044.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [72.2](/filings/0001724521-23-000021.md) | [73.0](/filings/0001724521-24-000092.md) | [73.2](/filings/0001724521-24-000138.md) | [74.6](/filings/0001724521-24-000160.md) | [86.2](/filings/0001724521-25-000063.md) | [91.1](/filings/0001724521-25-000101.md) | [91.4](/filings/0001724521-25-000116.md) | [98.4](/filings/0001724521-26-000034.md) | [107](/filings/0001724521-26-000044.md) | [107](/filings/0001724521-25-000116.md) | [125](/filings/0001724521-26-000034.md) | [126](/filings/0001724521-26-000044.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 127,333,376 at 2026-07-30, from the cover of the [10-Q filed 2026-08-05](/filings/0001724521-26-000044.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.